U.S. markets open in 6 hours 24 minutes

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.31-0.32 (-4.19%)
At close: 04:00PM EST
7.31 0.00 (0.00%)
After hours: 04:31PM EST

Organogenesis Holdings Inc.

85 Dan Road
Canton, MA 02021
United States
781 575 0775

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees910

Key Executives

NameTitlePayExercisedYear Born
Mr. Gary S. Gillheeney Sr.Pres, CEO & Director1.58MN/A1955
Mr. Patrick BilboChief Operating Officer719.31kN/A1962
Mr. Brian GrowChief Commercial Officer675.22kN/A1976
Mr. David C. FranciscoChief Financial OfficerN/AN/A1966
Ms. Lori H. FreedmanVP & Gen. CounselN/AN/A1967
Mr. Kurt MathesonVP of MarketingN/AN/AN/A
Mr. Thomas L. PearlVP of HRN/AN/AN/A
Dr. Zorina PitkinSr. VP of Quality SystemsN/AN/AN/A
Mr. Henry Hagopian IIISr. VP of Fin. & TreasurerN/AN/A1968
Mr. William R. Kolb CPASec.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Corporate Governance

Organogenesis Holdings Inc.’s ISS Governance QualityScore as of September 26, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.